---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-068910"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2023-06-07T23:59:59+00:00"
generated_at: "2026-06-14T05:53:19.155159+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Voyager Therapeutics stockholders elect three Class II directors at 2023 annual meeting

## Summary
- Elected Class II directors: Steven Hyman (20,552,674 for), James A. Geraghty (16,613,243 for), Alfred Sandrock (20,551,414 for); broker non-votes 8,405,461.
- Non-binding advisory say-on-pay approved with 20,162,995 for, 523,972 against, 33,553 abstain, and 8,405,461 broker non-votes.
- Ratified Ernst & Young as independent auditor for fiscal 2023 with 29,090,596 for, 32,521 against, 2,864 abstain.

## SEC filing metadata
- accession: 0001104659-23-068910
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2023-06-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000110465923068910/0001104659-23-068910-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000110465923068910/tm2318122d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-068910
- JSON: https://secwatch.observer/filing/0001104659-23-068910.json
- Plain text: https://secwatch.observer/filing/0001104659-23-068910.txt

## Key facts
- Shareholder Votes
  Voyager Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-06-06 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: Voyager’s stockholders ratified the appointment of Ernst & Young LLP as Voyager’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the stockholders’ vote with respect to such ratification were as follows: For Against Abstain Broker Non-Votes 29,090,596 32,521 2,864 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1640266/000110465923068910/0001104659-23-068910-index.htm
- Shareholder Votes
  Voyager Therapeutics, Inc. shareholders approved Election of Class II directors at the 2023-06-06 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: Voyager’s stockholders elected Steven Hyman, M.D., James A. Geraghty, and Alfred Sandrock, M.D., Ph.D., each to serve as a Class II director until the 2026 Annual Meeting of Stockholders and until his successor has been duly elected and qualified, subject to his earlier death, resignation, or removal. The results of the stockholders’ vote with respect to the election of such Class II directors were as follows: Name Votes For Votes Withheld Broker Non-Votes Steven Hyman, M.D. 20,552,674 167,846 8,405,461 James A. Geraghty 16,613,243 4,107,277 8,405,461 Alfred Sandrock, M.D., Ph.D. 20,551,414 169,106 8,405,461
  evidence_url: https://www.sec.gov/Archives/edgar/data/1640266/000110465923068910/0001104659-23-068910-index.htm
- Shareholder Votes
  Voyager Therapeutics, Inc. shareholders approved Non-binding advisory vote on executive compensation at the 2023-06-06 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: Voyager’s stockholders approved a non-binding, advisory proposal regarding the compensation of Voyager’s named executive officers. The results of the stockholders’ vote with respect to such proposal were as follows: For Against Abstain Broker Non-Votes 20,162,995 523,972 33,553 8,405,461
  evidence_url: https://www.sec.gov/Archives/edgar/data/1640266/000110465923068910/0001104659-23-068910-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.